The FDA's announcement marks the end of TIRF medications, controversial fentanyl formulations criticized for contributing to the opioid crisis amid scrutiny over their marketing practices.
Investigators discovered that Cephalon's sales teams had been violating FDA marketing regulations, persuading physicians to prescribe these potent medications beyond their intended use.
As of now, less than 150 patients are left on these TIRF medications, which allowed them to continue treatment only while supplies last amid regulatory changes.
Despite several investigations and lawsuits, the decision to stop sales raises questions regarding the future of stringent controls on opioid prescriptions and manufacturer accountability.
Collection
[
|
...
]